98%
921
2 minutes
20
There is a renewed interest for β-lactams for treating infections due to Mycobacterium tuberculosis and M. abscessus because their β-lactamases are inhibited by classical (clavulanate) or new generation (avibactam) inhibitors, respectively. Here, access to an azido derivative of the diazabicyclooctane (DBO) scaffold of avibactam for functionalization by the Huisgen-Sharpless cycloaddition reaction is reported. The amoxicillin-DBO combinations were active, indicating that the triazole ring is compatible with drug penetration (minimal inhibitory concentration of 16 μg mL for both species). Mechanistically, β-lactamase inhibition was not sufficient to account for the potentiation of amoxicillin by DBOs. Thus, the latter compounds were investigated as inhibitors of l,d-transpeptidases (Ldts), which are the main peptidoglycan polymerases in mycobacteria. The DBOs acted as slow-binding inhibitors of Ldts by S-carbamoylation indicating that optimization of DBOs for Ldt inhibition is an attractive strategy to obtain drugs selectively active on mycobacteria.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/chem.201800923 | DOI Listing |
Pathogens
July 2025
Department of Clinical Microbiology, Dr Andrija Štampar Teaching Institute of Public Health Zagreb, 10000 Zagreb, Croatia.
Background/objectives: is a frequent causative agent of urinary and wound infections in both community and hospital settings. It develops resistance to expanded-spectrum cephalosporins (ESCs) due to the production of extended-spectrum β-lactamases (ESBLs) or plasmid-mediated AmpC β-lactamases (p-AmpCs). Recently, carbapenem-resistant isolates of emerged due to the production of carbapenemases, mostly belonging to Ambler classes B and D.
View Article and Find Full Text PDFSci Rep
August 2025
IAME, UMR 1137, INSERM, Université Paris Cité, Paris, France.
Klebsiella pneumoniae carbapenemase (KPC) is a frequent and widespread carbapenemase, with over 260 variants identified. While KPC often evolves resistance to ceftazidime-avibactam, cefiderocol remains a key treatment option. Some variants, such as KPC-33 (D179Y), reduce cefiderocol susceptibility, but typically with only modest MIC increases.
View Article and Find Full Text PDFChina CDC Wkly
August 2025
State Key Laboratory of Microbial Metabolism, School of Life Sciences & Biotechnology, Shanghai Jiao Tong University, Shanghai, China.
What Is Already Known About This Topic?: Carbapenem-resistant (CRKP) poses a major threat to global health. The co-production of multiple carbapenemases has emerged as a critical concern, further limiting the effectiveness of last-resort antibiotics such as ceftazidime-avibactam.
What Is Added By This Report?: This study identifies an IncP6 plasmid co-harboring both and in a clinical isolate of .
Sci Rep
August 2025
Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
We characterized all ceftazidime-avibactam-resistant KPC-producing K. pneumoniae (KPC-Kp) isolates recovered from both patients and environmental samples at the ICU of our hospital in 2020, during the COVID-19 pandemic initiation. Antimicrobial susceptibility testing (Sensititre-EUMDROXF; disk-diffusion) and WGS analysis (Illumina-Novaseq/Miseq; Oxford Nanopore-MinION) were performed.
View Article and Find Full Text PDFDiagn Microbiol Infect Dis
December 2025
Department of Experimental Medicine, University of Salento, Via Provinciale Monteroni n. 165, Lecce 73100, Italy.
Introduction: Multi-carbapenemases producing Enterobacterales (MCP-EB) represents a new public health challenge due to their ability to display complex resistance phenotypes.
Methods: MCP-EB isolates identified from patients admitted to an Italian Center in the period 2020-2024 were included. Clinical features were collected.